search
Back to results

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

Primary Purpose

Type 1 Diabetes

Status
Enrolling by invitation
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
FAMS-T1D
Digital resources for diabetes
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Type 1 Diabetes focused on measuring Continuous glucose monitor, Social support, Goal setting, Diabetes distress, Hemoglobin A1c, Time in range, Emerging adults, Family support, Text message, Mobile health

Eligibility Criteria

18 Years - 24 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: PERSONS WITH DIABETES Ages 18-24 Have a diagnosis of T1D and has been taking insulin for at least one year Comfortable sending and receiving texts Can speak, read, and write in English Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2) Using a continuous glucose monitor (CGM) SUPPORT PERSONS Age 18 or older Can speak, read, and write in English or Spanish Comfortable sending and receiving texts Exclusion Criteria: PERSONS WITH DIABETES Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness) Plans to live outside the country during the study period SUPPORT PERSONS Shares a phone with the person with diabetes Plans to live outside of the country during the study period

Sites / Locations

  • Children's Hospital of Los Angeles
  • University of Utah

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

FAMS-T1D

Digital resources for diabetes

Arm Description

Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.

Outcomes

Primary Outcome Measures

CGM frequency of use during the intervention period
Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better
CGM frequency of use during the intervention period
Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)
Gaps in CGM use
Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)

Secondary Outcome Measures

CGM behavioral responses during the intervention period
Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)
Barriers to CGM use during the intervention period
Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
Barriers to CGM use during the intervention period
Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
CGM satisfaction during the intervention period
Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)

Full Information

First Posted
April 24, 2023
Last Updated
June 16, 2023
Sponsor
Vanderbilt University Medical Center
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, University of Utah, University of California, Merced, Children's Hospital Los Angeles
search

1. Study Identification

Unique Protocol Identification Number
NCT05854069
Brief Title
Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes
Official Title
Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
April 30, 2023 (Actual)
Primary Completion Date
January 31, 2027 (Anticipated)
Study Completion Date
April 30, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center
Collaborators
The Leona M. and Harry B. Helmsley Charitable Trust, University of Utah, University of California, Merced, Children's Hospital Los Angeles

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to evaluate the efficacy of an adapted FAMS (Family/friend Activation to Motivate Self-care) intervention on CGM use among study participants who are CGM users. We will leverage the infrastructure of an NIDDK-funded RCT evaluating FAMS-T1D among N=280 emerging adults with T1D who have elevated hemoglobin A1c or elevated diabetes distress (NCT05820477). We anticipate at least 50% using CGM to be included in these analyses.
Detailed Description
FAMS (Family/friend Activation to Motivate Self-care) is a mobile phone-delivered intervention, based on Family Systems Theory, which helps adults with diabetes set behavioral goals and improve support received from friends and family for goal success. FAMS includes monthly phone coaching and text message support by FAMS coaches for the person with diabetes (PWD) and the option to enroll a support person (SP) to receive automated texts tailored to the self-care goals the person with T1D sets in coaching sessions. Adaptations specific to CGM include the option to set CGM use goals in coaching (and receive associated text support) and skill-building exercises during coaching to support data sharing relationships (e.g., establishing, setting and adjusting ground rules about communication). Within the FAMS-T1D RCT (NCT05820477), we will test effects of FAMS-T1D on CGM use use relative to enhanced treatment as usual. We will evaluate effects on CGM use from baseline to post-intervention (6 months) as the primary endpoint. Study start date for the nested trial (NCT05854069) is the enrollment date of the first participant using a CGM. Since the goal of this trial is to assess effects of the adapted FAMS intervention on CGM use, the date participant CGM usage was confirmed is considered the enrollment date.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 1 Diabetes
Keywords
Continuous glucose monitor, Social support, Goal setting, Diabetes distress, Hemoglobin A1c, Time in range, Emerging adults, Family support, Text message, Mobile health

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
140 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
FAMS-T1D
Arm Type
Experimental
Arm Description
Participants will receive FAMS-T1D components (monthly phone coaching and text message support for goals) for 6 months. Support persons will receive text messages that are tailored to the goal set by the person with type 1 diabetes. All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
Arm Title
Digital resources for diabetes
Arm Type
Placebo Comparator
Arm Description
All persons with diabetes will receive text messages regarding how to access their HbA1c results and receive links providing information to assist them in self-care behaviors related to their diabetes. All support persons will also receive materials about type 1 diabetes and how to provide helpful support to the person with diabetes.
Intervention Type
Behavioral
Intervention Name(s)
FAMS-T1D
Other Intervention Name(s)
Family/friend Activation to Motivate Self-Care for those with Type 1 Diabetes
Intervention Description
FAMS-T1D involves monthly phone coaching that assists individuals in setting specific and time bound diabetes goals with automated text message support to the patient participant and less frequent automated text messages to their support person, if one is enrolled. Behavioral: Diabetes Resources High quality digital materials about diabetes management will be provided upon enrollment and send to participants quarterly.
Intervention Type
Behavioral
Intervention Name(s)
Digital resources for diabetes
Intervention Description
Quality digital resources about diabetes management provided upon enrollment and during the study.
Primary Outcome Measure Information:
Title
CGM frequency of use during the intervention period
Description
Change in CGM frequency of use assessed by self-report on questionnaire; more frequent use/higher is better
Time Frame
Baseline and 6 months post-baseline
Title
CGM frequency of use during the intervention period
Description
Change in CGM frequency of use assessed by objective CGM data (% of time; higher is better)
Time Frame
Baseline and 6 months post-baseline
Title
Gaps in CGM use
Description
Length of gaps in CGM use as assessed by objective CGM data (measured in number of consecutive days without CGM data; higher is worse)
Time Frame
6 months post-baseline
Secondary Outcome Measure Information:
Title
CGM behavioral responses during the intervention period
Description
Change in frequency of making behavioral changes in response to CGM data assessed by self-report; higher scores indicate more frequent response (better)
Time Frame
Baseline and 6 months post-baseline
Title
Barriers to CGM use during the intervention period
Description
Change in perceived influence of CGM on glycemic control scale assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
Time Frame
Baseline and 6 months post-baseline
Title
Barriers to CGM use during the intervention period
Description
Change in perceived influence of CGM on social complications assessed by Glucose Monitoring Survey; higher scores indicate more perceived problems with CGM use (worse)
Time Frame
Baseline and 6 months post-baseline
Title
CGM satisfaction during the intervention period
Description
Change in CGM satisfaction assessed by Benefits of CGM scale; higher scores indicate more perceived benefits of CGM use (better)
Time Frame
Baseline and 6 months post-baseline
Other Pre-specified Outcome Measures:
Title
Data sharing during the intervention period
Description
Number of data sharing relationships, between groups; more is better
Time Frame
6 months post-baseline
Title
Satisfaction with data-sharing relationships
Description
Satisfaction with data-sharing relationships assessed by CGM-Satisfaction Scale; higher scores are better
Time Frame
6 months post-baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
24 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: PERSONS WITH DIABETES Ages 18-24 Have a diagnosis of T1D and has been taking insulin for at least one year Comfortable sending and receiving texts Can speak, read, and write in English Meets one of the following two criteria: 1) has a most recent A1c value in the EHR that is 7.5% or higher (or missing) OR 2) screen positive for diabetes distress on the two-item Diabetes Distress Screen (DDS-2) Using a continuous glucose monitor (CGM) SUPPORT PERSONS Age 18 or older Can speak, read, and write in English or Spanish Comfortable sending and receiving texts Exclusion Criteria: PERSONS WITH DIABETES Has a condition that would prohibit study completion (intellectual disability, blindness or auditory limitations, severe mental illness) Plans to live outside the country during the study period SUPPORT PERSONS Shares a phone with the person with diabetes Plans to live outside of the country during the study period
Facility Information:
Facility Name
Children's Hospital of Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90027
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
After study results are posted on clinical trials and published, de-identified data will be available upon requests made to the principal investigator.
IPD Sharing Time Frame
After study results are posted on clinical trials and outcomes published in a peer-reviewed journal, until 5 years later.
IPD Sharing Access Criteria
Contact the principal investigator

Learn more about this trial

Adapting FAMS to Optimize CGM Use Among Emerging Adults With Type 1 Diabetes

We'll reach out to this number within 24 hrs